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The European Lead Factory (ELF) is a public–private partnership (PPP) that provides 
researchers in Europe with a unique platform for translation of innovative biology and 
chemistry into high-quality starting points for drug discovery. It combines an exceptional 
collection of small molecules, high-throughput screening (HTS) infrastructure, and 
hit follow-up capabilities to advance research projects from both private companies 
and publicly funded researchers. By active interactions with the wider European life 
science community, ELF connects and unites bright ideas, talent, and experience from 
several disciplines. As a result, ELF is a unique, collaborative lead generation engine 
that has so far resulted in >4,500 hit compounds with a defined biological activity 
from 83 successfully completed HTS and hit evaluation campaigns. The PPP has also 
produced more than 120,000 novel innovative library compounds that complement 
the 327,000 compounds contributed by the participating pharmaceutical companies. 
Intrinsic to its setup, ELF enables breakthroughs in areas with unmet medical and 
societal needs, where no individual entity would be able to create a comparable impact 
in such a short time.
Keywords: european Lead Factory, Joint european Compound Library, high-throughput screening, collaborative 
research, drug discovery, translational research, innovative Medicines initiative, public–private partnership
inTRODUCTiOn
While we continuously obtain a better understanding of disease-causing mechanisms, we still 
face a number of challenges when translating these findings into therapeutic products that reach 
patients’ needs (1, 2).
Innovation and discoveries derived from academic research institutes have great potential to be 
developed into clinically meaningful products; however, it is clear that these parties often lack the 
resources and experience to fully progress their findings toward the clinic. Traditional pharmaceutical 
Abbreviations: DD, drug discovery; ELF, European Lead Factory; ESC, European Screening Center; FDA, Food and Drug 
Administration; HDB, honest data broker; HTS, high-throughput screening; IMI, Innovative Medicines Initiative; IP, intel-
lectual property; IT, information technology; JECL, Joint European Compound Library; NTDs, neglected tropical diseases; 
PPP, public–private partnership; SME, small- to medium-sized enterprise.
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companies can build on decades of experience in bringing drug 
candidates successfully to patients. However, due to several well-
reported reasons (1–3), the traditional business model faces a gap 
between early discoveries and product development.
Despite large investments and advances in basic and applied 
pharmaceutical research in recent years, the success rate in drug 
discovery (DD) and development of innovative therapies in 
most disease areas has been low as a result of this translational 
gap (2, 3). Consequently, the substantial need for new drugs 
remains and poses a serious threat not only to patients but also 
to the welfare of modern society (4).
In response to this necessity for new solutions, the DD land-
scape is continuously adjusting itself to pursue a sustainable and 
more productive research and discovery model (5, 6). Currently, 
the precompetitive space in pharmaceutical research is being 
redefined, and more transparent and collaborative innovation 
approaches are increasingly being embarked upon. The objec-
tives are not only to share investment risks but also to minimize 
attrition rates of DD, pool complementary talents and resources, 
provide sustainable infrastructure platforms where different 
players have access to the brightest ideas and are able to interact 
liberally, and exchange collective solutions to problems arising in 
the DD process (7). Public–private partnerships (PPPs) are the 
tool of choice for bridging this gap (8, 9).
Small molecule therapy remains one of the cornerstones of 
modern medicine. Approximately 90% of all the therapeutics 
sold are based on small molecule drugs. The Food and Drug 
Administration’s Centre for Drug evaluation and research, which 
oversees the approval of new drugs, approved 45 new drugs in 
2015. This marks a 19-year high after hitting a low of 18 new 
approved drugs in 2007 (10). Out of the new drugs approved in 
2015, two-thirds are derived from small molecular entities. This 
exemplifies the fact that a significant number of new medicines 
introduced are derived from chemical compound collections.
High-throughput screening (HTS) is an effective and well-
established methodology to assess the biological effect of large 
collections of chemical compounds. This methodology has 
matured over the years at large pharmaceutical companies and 
has generated more new active pharmaceutical ingredients than 
any other rational DD approach (11). However, the success of an 
HTS campaign highly depends on the quality of the compound 
collection, the infrastructure, the assays, i.e., how to read out 
the biological response of the screening compounds, and the 
data interpretation skills (12). Hence, expertise and experience 
from a broad range of specific life sciences must be collected and 
amalgamated.
With this in mind, the Innovative Medicines Initiative’s 
(IMI) European Lead Factory (ELF) project was launched, with 
an aim to create a collaborative PPP DD platform to seed and 
execute early-stage projects more effectively (13). By combining 
an industry-standard HTS infrastructure (European Screening 
Centre), a state-of-the-art Joint European Compound Library 
(JECL) and newly developed information technology (IT) solu-
tions, ELF enables any European biotech company or research 
institute to access, free of charge, tools, resources, and know-how 
that were once available exclusively in the large pharmaceutical 
companies (14).
eLF: A COLLABORATive eARLY 
DD eFFORT
European Lead Factory is unique in its reach, with interaction 
points for organizations of all sizes: from single individuals 
who can submit chemical library ideas and/or disease-related 
targets, up to the participating multinational pharmaceutical 
companies (Figure 1). This heterogeneity is also reflected in the 
core team of the ELF: it comprises 7 established pharmaceutical 
companies, 10 small- to medium-sized enterprises (SMEs), and 
13 academic partners, who collaborate in a precompetitive mode 
(14). Crowdsourcing of innovative chemistry and biology allows 
the project to be at the forefront of these respective fields, while 
equipping the DD community with high-quality starting points. 
ELF operates as a translational hub, to which scientists from SMEs 
and academia, from all over Europe, can submit their ideas and 
have those translated into tangible assets that can be developed 
internally or in collaboration with partners (Figure 1). In addi-
tion, by combining innovative ideas in chemistry and biology, 
it opens up new areas that have yet not been explored by those 
currently working on DD projects.
SMes AS An iMPORTAnT DRiveR 
FOR SUCCeSS in PPPs
Public–private partnerships are, at the onset, often accused of 
a certain degree of inertia that results from a complex partner 
mix, opposing interests, democratic decision-making, and high 
demand of transparency. ELF has circumvented this and man-
aged to be highly effective and fully operational within a year 
through a clear governance structure, intellectual property (IP) 
regulation, IT software solutions, in combination with the drive 
of the ELF partners to deliver valuable output for the benefit of 
the wider community. This partnership works much beyond the 
objectives of any single partner.
Certainly, the high ratio of SME involvement in ELF has had 
a pivotal role in accelerating many processes. SMEs have over the 
past decade worked closely with and for the larger pharmaceuti-
cal industry, as well as with public research institutes in early 
DD projects. ELF has provided the SMEs with a showground to 
further prove their abilities. The participating SMEs are instru-
mental in implementing the production and management of the 
compound library and performing the screening. Their agility 
and emphasis on producing results has had a professional influ-
ence on the ELF machinery, making it the well-oiled initiative 
it is today.
While academia and SMEs inject innovation and execution 
power to the PPP, the established pharmaceutical companies 
provide the means and experience to develop the scientific 
discovery of biologically active molecules into medical therapies. 
The extensive drug development expertise available in pharma-
ceutical companies provides opportunities to academics and 
biotechs to valorize the results either in downstream alliances 
along the pharmaceutical value chain, through license agree-
ments around generated IP, or through the generation of spin-
outs based on assets generated within their ELF participation.
FiGURe 1 | european Lead Factory is a translational hub. It uses the collective intelligence in the European life science community to connect disease-related 
targets (provided by target owners) with high-quality small molecules (based on library design ideas or provided by established pharmaceutical companies) resulting 
in compounds with a defined biological activity. Many types of outcomes are fed back to the community with the ultimate aim of benefiting public health.
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THe eLF MODe OF ACTiOn
Now fully operational, the ELF provides a unique platform for 
translation of innovative biology and chemistry into high-quality 
starting points for DD. This cohesive PPP contains three essential 
assets for bridging the innovation gap of early DD: (i) access to 
a state-of-the-art chemical compound collection (15, 16), (ii) 
access to screening facilities of industrial standards, and (iii) 
access to the expertise required to convert the obtained results 
and data into potential drug candidates.
JOinT eUROPeAn COMPOUnD LiBRARY
The quality and diversity of the compound collection is of upmost 
importance in DD. The JECL is one of the strongest assets of the 
consortium. It constitutes a collection of starting points for new 
therapies and consists of two parts: the pharmaceutical industry 
compound collection and the public compound collection. 
At the onset of the project, over 327,000 high-quality compounds 
were contributed by the seven pharmaceutical industry partners 
within the consortium according to exacting selection criteria 
agreed upon by the participating partners. Within the time frame 
of ELF, these compounds are being complemented with up to 
200,000 newly synthesized compounds (15).
In return for their compound contributions, the participating 
pharmaceutical companies have access to the entire compound 
collection for screening a limited number of internal targets. In 
this way, ELF provides a neutral platform that allows different 
companies to access their competitors’ compound libraries. By 
combining screening compounds from different sources, more 
target classes are being addressed than by anyone single source, 
opening up for the revitalization of discovery projects at the 
participating pharmaceutical industry partner, which have failed 
to produce attractive hits in in-house campaigns. Consequently, 
the available chemical space is being utilized more efficaciously. 
To date, an impressive one-third of the finished ELF industry 
projects have triggered additional drug development efforts at 
the respective company. Activating such projects will eventually 
benefit the patients, who have an increased chance for new 
therapies.
Out of the 200,000 novel compounds targeted, over 100,000, 
based on more than 220 scaffolds (molecular frameworks), are 
already synthesized and available to the European Research 
Community midway through the project (16). More than 500 
library ideas have been selected and evaluated to be processed 
within ELF. This new compound collection is based on proposals 
that are submitted by chemists—from either within or outside 
the consortium—using a step-by-step procedure via a web-based 
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tool (17). The compound collection is unique and diverse com-
pared to commercial sources and typical chemical compound 
repositories.
When submitting library proposals to ELF, external contribu-
tors retain the right to continue doing research on the chemical 
entities and to publish their own research and findings. Only an 
exclusive set of compounds that is being synthesized within ELF 
is being kept proprietary. In order to ensure the quality of the pro-
duced library, submitted library proposals are being assessed by a 
Library Selection Committee. It consists of eight members from 
the pharmaceutical industry, SMEs, and academia, all bound by 
confidentiality, in order to provide broad and complementary 
chemistry and DD expertise, thereby ensuring a high-quality 
library. The data and information provided at a library proposal 
stage are used to assess the original proposals against six specific 
drug relevant selection criteria: novelty, molecular properties, 
synthetic tractability, diversity potential, structural features, and 
innovative library design. Furthermore, molecular properties and 
structural features should be preferably aligned to contemporary 
hit- and lead-like properties (15).
Given the size and heterogeneity of the chemistry partners 
within the ELF consortium (23 out of the 30 partners are involved 
in the chemistry activities), chemistry project management is 
critical to its success. Real-time monitoring, data storage, and 
decision-making are enabled by TarosGate 2, a secure informat-
ics platform, which seamlessly connects the chemistry labora-
tories of the academic and SME partners. Since the software 
covers three important aspects of the decentralized collaborative 
work: (i) work documentation as an electronical lab journal, 
(ii) management of the project, and (iii) communication, it has 
a noticeable impact on the operational speed of the chemistry 
consortium.
eUROPeAn SCReeninG CenTeR (eSC)
One of the greatest challenges in the postgenomic era is how to 
translate the host of genetic knowledge into drug targets, i.e., 
proteins or biological structures, which can be modulated to 
give a desired biological effect. The number of available targets 
is greater than ever. To dissect which ones are worth pursuing 
has proven difficult and associated with a great need of highly 
interdisciplinary collaborations. A researcher at any European 
SME or academic institute is welcome to submit a proposal 
to ELF for screening his or her drug target. The proposals are 
reviewed based on scientific value and technical maturity. The last 
is defined by the requirements for the screening assay, which has 
to be compatible with HTS and executable in well plates, together 
with the availability of complementary assays to further refine the 
hit compound selection.
The drug targets selected from the European life science 
community are being screened at the ESC. Once the assay is 
transferred, the work begins by optimizing it further. After a first 
screen against all available compounds in the collection (cur-
rently over 400,000), the so-called primary hits (typically a few 
thousands) are further evaluated to confirm engagement with the 
defined drug target and to establish activity levels of desired and 
undesired biological effects. At this point, three to five different 
types of assays have been applied and the number of interesting 
compounds is narrowed down to typically a few hundreds. The 
ELF medicinal chemists make the final selection of the best ≤50 
compounds, based on information provided by the researcher 
who proposed the target and the purpose of the research (drugs 
vs. tool compounds) (12).
As of end of August 2016, 72 public target projects have been 
selected by ELF. In order to extract the most interesting com-
pounds for these projects, more than a total of 150 biochemical, 
cellular, and biophysical assays have been developed, 49 HTS have 
been completed and over 1,000 compounds have been granted 
to owners of public target projects that can serve as potential 
new starting points for DD projects. Further work to validate 
the selected compounds have been performed for 23 of the 30 
projects. In this process, >1,500 bespoke compounds have been 
synthesized by the ELF medicinal chemists and provided to their 
target owners.
From the very start, ELF aimed for non-discriminating 
crowdsourcing activity with a special focus on innovation. 
As a consequence, the current drug target project portfolio is 
complementary and clearly different from the industry (13, 18). 
It includes many targets considered as highly challenging, such 
as protein–protein or protein–DNA/RNA interactions (15% of 
the projects), and very few of the most pursued target types, e.g., 
kinases (7%) and proteases (4%) (Figure 2A). Interestingly, the 
stringent requirement for an HTS-compatible assay format does 
not seem to have affected the innovative aspect on target level. 
Although the projects are spread over a wide range of disease 
areas, illustrated in Figure 2B, there is a high proportion of oncol-
ogy projects (42%). This might be a reflection of the relatively 
abundant funding opportunities for cancer research, leading to a 
higher chance of accessing the infrastructure needed to develop 
an HTS-compatible assay. The aspiration for societal benefit is 
illustrated by the number of projects in infectious diseases (18% 
in total). In fact, ELF recently lowered the hurdles for non-profit 
DD projects in the area of neglected tropical diseases, freeing 
charities, and other organizations from financial obligations in 
their pursuit of new therapies for patients in the least developed 
countries (18).
It is important to emphasize that the control and IP rights 
of the biology drug target projects remain with the original 
proposer. This secures the involvement of the biology experts 
within the ELF to efficiently use the collective intelligence in 
translating the findings into clinically relevant small molecules. 
A fit-for-purpose IP framework allows successful projects to 
be further progressed to clinical studies, while research use of 
results is facilitated. ELF projects derived from academia and 
SMEs choosing to look for a commercial partner have to provide 
the ELF pharmaceutical industry partners with a right of first 
option, which the target owner have the right to refuse. For 
the participating industry partners, this provides an additional 
opportunity to have insight into novel innovative drug targets 
that these pharmaceutical companies would not have access to. 
The Honest Data Broker is a consortium software developed 
specifically for ELF to balance the scientific and IP require-
ments of all the involved parties. It ensures that all the partners 
work together in a productive, and where required, transparent 
FiGURe 2 | Character of crowdsourced disease-related target projects accepted by european Lead Factory (eLF) as of August 31, 2016. (A) Nature of 
molecular drug target. (B) Main therapeutic area addressed by the projects.
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environment, as one single unit, despite the different nature and 
interests of the various participating stakeholders (academia—
SME—pharmaceutical industry) (19).
COnCLUSiOn
Three years after the start of the project, ELF has matured from 
a start-up initiative to a well-organized group of over 150 sci-
entists. Experts from all essential areas of early DD—industry, 
academia, and SMEs—now jointly produce high-quality output 
for the wider public benefit. In this time, the PPP has published 
>30 articles and the results from the first crowdsourced ideas 
gradually disseminate in the public domain for everyone to assess 
(6, 12, 13, 15, 19–48).
At the time of writing this paper, researchers from 13 countries 
are involved, one spin-out company has been established, and 
patents have been filed by academic research groups based on 
the screening results of their submitted screening proposals to the 
ELF. Over 120,000 new compounds have been synthesized and 
added to the screening library. So far, 72 screening programs have 
been accepted from European academic groups and biotechs and 
are currently being processed.
The resulting biologically active compounds are used by bio-
techs to further progress their DD programs, by universities to be 
optimized toward potential therapies, or used as chemical tools to 
support groundbreaking basic research. For the pharmaceutical 
industry partners, currently 17 out of 49 screening campaigns 
with the ELF compound library have triggered further work 
within the companies.
A less tangible, but just as important, outcome of this PPP is 
the impact it has on the human capital involved. The constant flow 
of knowledge exchange between scientists in different disciplines 
and organizations inside and outside ELF allows to fully capitalize 
on the collective intelligence.
OUTLOOK
Unmet medical needs still prevail in nearly all indication areas. 
Although several initiatives have been launched in the past few 
years on a regional, national, or international scale (49–53), ELF 
is the first effectively operating pan-European initiative embrac-
ing both the public and private sectors.
European Lead Factory provides a unique platform for 
connecting innovative biology and novel chemistry into high-
quality starting points for DD. Intrinsic to its setup, ELF enables 
breakthroughs in areas with unmet medical needs, where no 
individual entity would be able to create a comparable impact in 
such a short time.
With an active life science community in Europe, the results 
will be absorbed and further developed into clinically meaningful 
drug candidates. While having bridged a major gap in develop-
ing innovation in chemistry and biology toward an interesting 
DD project, it is already clear that the next translational gap is 
already emerging. Valuable compounds derived from JECL have 
now been extensively tested in  vitro and have seen some pre-
clinical in vivo models, but the subsequent development of those 
compounds into drug candidates needs the next push. Currently, 
some of the DD projects flow into other initiatives within the IMI 
portfolio, or are under evaluation by other funding organizations 
such as the Wellcome Trust or pharmaceutical companies to be 
further developed. Facilitating such a subsequent step will be an 
important driver to increase the long-term impact of ELF on the 
European community. Together with the essential stakeholders 
for the next phase, these types of PPPs can jointly shape the future 
6Karawajczyk et al. The European Lead Factory
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of medicine. In fact, ELF could serve as a blueprint of how future 
PPPs might operate in order to efficiently find cures that could 
reach patients in dire need of new treatments.
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